![Jan Skvarka](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jan Skvarka
Directeur/Membre du Conseil chez
ZENTALIS PHARMACEUTICALS, INC.
Fortune : 1 M $ au 31/05/2026
Profil
Jan Skvarka is Executive Chairman at DEM BioPharma, Inc. since 2024.
Dr. Skvarka is Independent Director at Zentalis Pharmaceuticals, Inc. since 2022.
Dr. Skvarka is Independent Director at Monte Rosa Therapeutics, Inc. since 2023.
Former roles include President, Chief Executive Officer & Director at Trillium Therapeutics, Inc. from 2019 to 2021; President, Chief Executive Officer & Director at Tal Medical, Inc. from 2014 to 2019; Executive Chairman at GentiBio, Inc. in 2022; Partner-Healthcare Practice at Bain & Co., Inc.; and Manager at PricewaterhouseCoopers LLP (United Kingdom).
Education includes a doctorate from the University of Bratislava Economic and an MBA from Harvard Business School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 16/06/2026 | 264 254 ( 0,37 % ) | 1 M $ | 31/05/2026 | |
| 11/06/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
Postes actifs de Jan Skvarka
| Sociétés | Poste | Début |
|---|---|---|
| ZENTALIS PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 12/09/2022 |
| MONTE ROSA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/03/2023 |
DEM BioPharma, Inc.
 DEM BioPharma, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biopharmaceutical company that manufactures cancer therapeutics | Président | 01/03/2024 |
Anciens postes connus de Jan Skvarka
| Sociétés | Poste | Fin |
|---|---|---|
GentiBio, Inc.
 GentiBio, Inc. BiotechnologyHealth Technology Develops regulatory T-cells for allergic diseases | Président | 01/11/2022 |
| TRILLIUM THERAPEUTICS | Directeur Général | 17/11/2021 |
Tal Medical, Inc.
 Tal Medical, Inc. Medical SpecialtiesHealth Technology Operates as a clinical stage medical device company | Directeur Général | 01/01/2019 |
PricewaterhouseCoopers LLP (United Kingdom)
 PricewaterhouseCoopers LLP (United Kingdom) Miscellaneous Commercial ServicesCommercial Services Provides audit, tax, legal, advisory and consulting services | Corporate Officer/Principal | - |
Bain & Co., Inc.
 Bain & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Provides strategy, marketing, organization, operations, IT and M&A consulting services | Corporate Officer/Principal | - |
Formation de Jan Skvarka
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
18
Relations au 1er degré
10
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
Trillium Therapeutics, Inc.
 Trillium Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Researches, develops and manufactures medicines & therapies for cancer | Health Technology |
Tal Medical, Inc.
Tal Medical, Inc. Medical SpecialtiesHealth Technology Operates as a clinical stage medical device company | Health Technology |
Bain & Co., Inc.
Bain & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Provides strategy, marketing, organization, operations, IT and M&A consulting services | Commercial Services |
PricewaterhouseCoopers LLP (United Kingdom)
PricewaterhouseCoopers LLP (United Kingdom) Miscellaneous Commercial ServicesCommercial Services Provides audit, tax, legal, advisory and consulting services | Commercial Services |
University of Bratislava Economic
 University of Bratislava Economic Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Zentalis Pharmaceuticals, Inc.
 Zentalis Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops clinical therapeutics for targeting fundamental cancer pathways | Health Technology |
GentiBio, Inc.
GentiBio, Inc. BiotechnologyHealth Technology Develops regulatory T-cells for allergic diseases | Health Technology |
Monte Rosa Therapeutics, Inc.
 Monte Rosa Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops molecular glue degrader medicines for oncology, autoimmune and inflammatory diseases | Health Technology |
DEM BioPharma, Inc.
DEM BioPharma, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biopharmaceutical company that manufactures cancer therapeutics | Commercial Services |
